凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)
Multiplex Assay Kit for Thrombin/Antithrombin Complex (TAT) ,etc. by CBA (Cytometric Bead Array)
- 編號(hào)CMA831Hu
- 物種Homo sapiens (Human，人)相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)4h
- 檢測(cè)范圍0.3906-400pg/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.1302pg/mL.
- 樣本類(lèi)型Plasma
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格48T96T
- 價(jià)格¥ 2822¥ 4032
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 86-93 | 90 |
| EDTA plasma(n=5) | 95-103 | 99 |
| heparin plasma(n=5) | 85-99 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線(xiàn)性
在定值血清及血漿樣本內(nèi)加入適量的凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線(xiàn)性范圍即為稀釋后樣本中凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-101% | 97-104% | 83-96% | 80-89% |
| EDTA plasma(n=5) | 90-98% | 78-89% | 93-101% | 88-96% |
| heparin plasma(n=5) | 86-94% | 81-104% | 98-105% | 93-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1、向?qū)嶒?yàn)板每孔內(nèi)加入200μL分析緩沖液以預(yù)濕；
2、實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
3、加樣（標(biāo)準(zhǔn)品、樣本、磁珠），標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，25°C酶標(biāo)板振蕩器孵育2小時(shí)；
4、磁吸甩干，加檢測(cè)溶液A 100μL，25°C酶標(biāo)板振蕩器孵育1小時(shí)；
5、磁吸甩干，加檢測(cè)溶液B 100μL，25°C振動(dòng)孵育30分鐘；
6、磁吸洗板1次；
7、加鞘液100μL，旋渦震蕩10分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)抗體包被于磁性微球表面，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)抗體，加入PE標(biāo)記的親和素，用流式細(xì)胞儀讀數(shù)。MFI值和樣品中的凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法)濃度呈正相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| EPA831Hu61 | 凝血酶/抗凝血酶復(fù)合體(TAT)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA831Hu01 | 凝血酶/抗凝血酶復(fù)合體(TAT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| MAA831Hu21 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu24 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu25 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu22 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu23 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | WB |
| MAA831Hu27 | 凝血酶/抗凝血酶復(fù)合體(TAT)單克隆抗體 | ICC/IF |
| SEA831Hu | 凝血酶/抗凝血酶復(fù)合體(TAT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA831Hu | 凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| CMA831Hu | 凝血酶/抗凝血酶復(fù)合體(TAT)等多因子檢測(cè)試劑盒(流式熒光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| IUBMB LIFE | Genetic repression of mouse VEGF expression regulates coagulation cascade.[PubMed: 21086498] |
| Thrombosis Research | Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice[ScienceDirect: S0049384811004166] |
| Journal of Thrombosis and Haemostasis | High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality[Wiley: source] |
| 3 | Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling[Nature: 20120329] |
| Am J Respir Cell Mol Bio | Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury[PubMed: PMC2993087] |
| PLoS One | Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis[PubMed: PMC3521733] |
| Haemetology | Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India[Pubmed: 23992124] |
| Am J Transl Res. | Selected hemostatic parameters in patients with pancreatic tumors.[Pubmed:Pmc4297344] |
| PLOS ONE | TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response[Pubmed:24489651] |
| Leukemia | Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs)[Pubmed:24667943] |
| Anesthesia & Analgesia | Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in Mice[Pubmed:24781566] |
| Cell Transplantation | Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral Blood[Pubmed:26087465] |
| European Journal of Pharmacology | (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lation[Pubmed:27343380] |
| J Thromb Haemost. | Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis.[pubmed:27813324] |
| Blood Cells, Inflammation and Infection | Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury[pubmed:29202212] |
| SCIENCE TRANSLATIONAL MEDICINE | Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension[pubmed:28148841] |
| 32 | Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target[pubmed:28289017] |
| Thrombosis?andHaemostasis | Nebulized anti-coagulants as a therapy for acute lung injury and acute respiratory distress syndrome[Pubmed: 29202212] |
| Thrombosis Research | The circadian rhythm of selected parameters of the hemostasis system in healthy people[] |
| Experimental Neurobiology | Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced Damage[Pubmed: 31698553] |
| LIVER TRANSPLANTATION | The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia‐reperfusion injury in mice[Pubmed: 33108682] |
| Am J Physiol Heart Circ Physiol | Doxorubicin contributes to thrombus formation and vascular injury via enhancing platelet functions in vivo[Pubmed: 32469636] |
| Intensive Care Medicine Experimental | Preservation of renal endothelial integrity and reduction of renal edema by aprotinin does not preserve renal perfusion and function following experimental?…[34169407] |
| Intensive Care Med Exp | Complement factor D is linked to platelet activation in human and rodent sepsis[34396466] |